44 results about "Cartilage degradation" patented technology

Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

Methods for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule containing the DNA sequence encoding for the product and infecting the target cell of the mammalian host using the vector. The injection can be done in vivo, by directly injecting the vector into the host, or can be done in vitro by transfecting a population of cultured target cells with the vector and transplanting them each into the host. Nonviral means can also be used to introduce the DNA sequence to the host. Administration of more than one gene of interest results in an enhanced therapeutic benefit. Also disclosed is a method for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a joint of a host for use in treating multiple joints of the host. Injection of a vector molecule containing the DNA sequence encoding for a product of interest, or non-viral introduction of such a DNA sequence, to one join of a mammalian host results in a therapeutic benefit in that joint as well as other joints in the host

The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

A method for decreasing cartilage abnormalities and preventing cartilage degradation in an animal using a combination at least one sulfur containing amino acid and manganese.

The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

The invention discloses a cartilage extracellular matrix and silk fibroin composite orientation cartilage support and a preparation method thereof and belongs to the biological tissue engineering technology. According to the cartilage extracellular matrix and silk fibroin composite orientation cartilage support and the preparation method of the cartilage support, cartilage extracellular matrixes are prepared through articular cartilage of people, pigs, cows or sheep, silk fibroin is prepared through mulberry silk, after the cartilage extracellular matrixes and the silk fibroin are evenly mixed according to a specific proportion, directed crystallization is performed under a certain temperature, ultraviolet cross linking is firstly performed after freezing and drying, and then cross linking of carbodiimide and N-hydroxysuccinimide or glutaraldehyde and genipin is performed so that the cartilage extracellular matrix and silk fibroin composite orientation cartilage support can be prepared. Due to the design, biocompatibility is good, and immunological rejective reaction is avoided; a composition structure and mechanical properties are similar to those of cartilage extracellular matrixes of people; material sources are wide, cost is low, the preparation technology is simple, the cartilage extracellular matrix and silk fibroin composite orientation cartilage support can be used for constructing tissue engineering cartilage and repairing cartilage degradation, and clinical application prospects are good.

The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R¹ and R² is H, and the other is selected from F and Cl, or R¹ and R² are both F; R³ is selected from cyclopentyl and cyclohexyl; R⁴ is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

The invention relates to the field of pharmaceuticals, dietary supplements and food and, more specifically, to the field of dietary supplements intended for the treatment of degradation of cartilage of any origin. The invention relates to liquid or paste compositions based on glucosamin and chondroitin sulphate, intended to provide elements essential for the synthesis and formation of proteoglycans, in which the chondroitin sulphate/glucosamin combination is stabilised with the addition of carboxylic acids such that the pH of the medium is between 2 and 5 and the chemical degradation rate of the active substances is less than 10% when stored at 25° C. and 60% relative humidity for 10 months for doses of between 300 and 2400 mg chondroitin sulphate and between 500 and 3000 mg glucosamin. The invention is suitable for the treatment of cartilage degradation and, more specifically, arthrosis.

The invention discloses an SHP2 allosteric inhibitor SHP099 for treating osteoarthritis (OA). Aiming at a DMM model and a natural aging induced mouse OA disease model, the SHP099 can effectively inhibit mouse knee joint cartilage defects and promote cartilage repair effects. At the cellular level, the SHP099 remarkably reduces the level of cartilage degrading enzyme under the stimulation of IL-1beta and promotes the expression of cartilage synthesis genes, so that dual regulation on cartilage synthesis and catabolism are realized. In addition, the SHP099 also has the effect of promoting cartilage cell differentiation at a concentration gradient.

The invention discloses application of resorcylic acid lactone 5Z-7 in preparation of a medicament for treating osteoarthritis and belongs to the field of biological medicines. The resorcylic acid lactone 5Z-7 is a small-molecule inhibitor for TAK1, and activation of immuno-associated pathway, such as NF-kB, p38 and JNK mediated by inflammatory cytolines and a matrix degradation product in synovium and cartilage tissue can be inhibited through targeted inhibition of the enzymatic activity of the TAK1 in an articular cavity, thereby achieving the targets of reducing synovial inflammatory response, inhibiting cartilage degradation and improving the microenvironment of the articular cavity through controlling a series of gene expression related to the osteoarthritis on the downstream of the pathways; the resorcylic acid lactone 5Z-7 is of great significance in delaying the osteoarthritis process and effectively treating the osteoarthritis. In addition, the resorcylic acid lactone 5Z-7 is taken as a small molecule compound, the action target is single and high in specificity, and the resorcylic acid lactone 5Z-7 is free of a toxic or side effect on cartilage tissue through detection, and is safer and more reliable.

The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.

The invention provides a method for determining the efficacy of compositions used to treat articular joint conditions in mammals. The method includes measuring the change in levels of one or more cartilage degradation biomarkers in a mammal from before exercise and after exercise, then administering a composition used to treat articular joint conditions to the mammal, and measuring the change in levels of one or more cartilage degradation biomarkers in the mammal from before exercise and after exercise.

The role of the JAK/STAT signal transduction pathway cellular mechanisms that lead to the onset and progression of degenerative joint diseases or disorders such as osteoarthritis (OA) is disclosed. Certain known effective OA therapeutics such as hymenialdisine, debromohymenialdisine, and its variants and derivatives are shown to function as JAK3-specific inhibitors, which downregulate steady state mRNA levels of key cellular components involved in cartilage degradation. Another JAK3-specific inhibitor, not previously known as an OA therapeutic, is shown to downregulate steady state mRNA levels of various cellular components involved in cartilage degradation in a manner identical to that of the known OA therapeutics.

The invention discloses application of anemonin in the preparation of medicines for treating osteoarthritis. After a mouse with the osteoarthritis is treated by virtue of anemonin, the degradation of joint cartilages and the hypertrophy of cartilages can be restrained, and the expression quantities of MMP13 and Collagen X are reduced. According to the application, the pharmaceutical use of anemonin is broadened, a new drug for treating the osteoarthritis by preventing the degradation cartilage matrixes and the abnormal hypertrophy of cartilage cells, and diseases can be treated based on the pathogenesis of the osteoarthritis in a targeted manner; the application has a very important significance on the clinic treatment of the osteoarthritis.

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof,

wherein:

• X is CH or N; and
• R⁴ is optionally substituted C_3-8 alkyl or optionally substituted C_3-8 cycloalkyl.

The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.